SGLT2 inhibitors have shown benefit in reducing proteinuria and slowing CKD progression in native IgAN [14, 15], but transplant data are limited; use should be individualized with close monitoring for hemodynamic effects and infections. This evidence concerns the gene SLC5A2 and infection.